Polycystic ovary syndrome (PCOS) is strongly associated with hyperinsulinaemia and type II diabetes (T2D). Sequence variation within KCNJ11 (encoding Kir6.2, the beta-cell inwardly rectifying potassium channel) is implicated in the pathogenesis of neonatal diabetes, hyperinsulinaemia of infancy and multifactorial T2D. Comprehensive tagging studies have demonstrated that the KCNJ11 E23K variant (or ABCC8 A1369S in LD40.9) is responsible for the known association between KCNJ11 and T2D. Given the phenotypic overlap between PCOS and T2D, we investigated whether E23K is involved in susceptibility to PCOS and related traits. Case -control analyses for the KCNJ11 E23K variant were performed in (a) 374 PCOS cases and 2574 controls of UK British/Irish origin, and (b) 550 women with PCOS symptoms and 1114 controls from a Finnish birth cohort. The relationship between E23K genotype and androgen levels (a key intermediate phenotype relevant to PCOS) in 1380 samples was studied. The UK case-control analysis revealed no association between E23K genotypes and PCOS status (P ¼ 0.49; Cochran -Armitage test), and no significant relationship between E23K genotype and androgen measures in the samples for which these phenotypes were available (P ¼ 0.19). Similarly, the Finnish case-control analysis showed no association between E23K genotypes and PCOS status (P ¼ 0.75; Cochran -Armitage test), and no significant relationship between E23K genotype and androgen measures in the samples for which these phenotypes were available (Finnish controls, P ¼ 0.25; Finnish cases, P ¼ 0.08). In conclusion, these data (involving 44600 subjects) provide no evidence that common variants of the KCNJ11 E23K polymorphism have a major influence on PCOS susceptibility, though modest effect sizes (ORo1.25) cannot be excluded.
Introduction
Polycystic ovary syndrome (PCOS) is the commonest female endocrinopathy, affecting up to 10% of premenopausal women. 1 As well as the characteristic endocrine and reproductive features, women with PCOS frequently display profound metabolic disturbances. The risk of type II diabetes (T2D) in women with PCOS is approximately twice that of age-and BMI-matched controls. 2 Although the aetiology of PCOS remains poorly understood, hyperinsulinaemia clearly plays an important role. Measures that reduce insulin resistance and hyperinsulinaemia improve both the metabolic and reproductive features of PCOS. 3 -5 The adverse effects of hyperinsulinaemia are mediated via actions in numerous tissues including ovary, adrenal, 6 -8 pituitary 9, 10 and liver (through suppressed synthesis of sex hormone-binding globulin (SHBG)). 11, 12 Despite compelling evidence that PCOS has a significant heritable component, the variants responsible have yet to be defined, 6 although there is promising evidence of a susceptibility effect on chromosome 19p13.2. 13 Given the central role of insulin to PCOS pathogenesis, those genes whose products influence either the secretion or action of insulin represent important potential candidates. One such gene (KCNJ11) encodes the inwardly rectifying potassium channel (Kir6.2), an essential component of the beta-cell ATP-sensitive potassium (K ATP ) channel.
Rare mutations in KCNJ11
14 can lead to neonatal diabetes and hyperinsulinaemia of infancy (depending on the direction of their effect on channel function). 15 Previous comprehensive tagging studies have demonstrated that common variation within the single exon of KCNJ11, in particular the E23K variant (which is in almost complete LD (40.9) with the A1369S variant within the neighbouring ABCC8 but with no other nonsynonymous variants in KCNJ11), is heavily implicated in susceptibility to multifactorial T2D. 16 Furthermore, E23K is the polymorphism within KCNJ11 most likely to be aetiological for T2D, on both statistical and functional grounds. 16 -19 Given the strong metabolic, physiological and epidemiological overlap between PCOS and T2D (thereby obviating the need for retagging of KCNJ11 in PCOS), we set out to test the hypothesis that the E23K polymorphism might impact on PCOS risk, through case-control studies and analysis of androgen levels as a continuous phenotype relevant to PCOS.
Materials and methods
UK case -control analysis All of the UK cases have PCOS as defined by the 2003 Rotterdam consensus. 20 The cases were recruited as described previously. 21 All had presented with menstrual disturbances (oligo-or amenorrhoea defined as an intermenstrual interval 442 days) and/or hyperandrogenism and had ultrasound-confirmed polycystic ovarian (PCO) morphology. 22 
Finnish birth cohort
We also studied 1664 women from the Northern Finland Birth Cohort of 1966 (NFBC66). 23 These were selected from a total of 3115 cohort women who were examined at age 31 years and who consented for research use of their data. Those selected included 550 women with symptoms of PCOS (hirsutism and/or oligo-amenorrhoea defined as 'an intermenstrual interval 435 days') at age 31 years and 1114 control women (who reported no such symptoms). The former group ('symptomatic cases') have biochemical features -as a group -consistent with PCOS. 24, 25 Because these cases do not reach the 2003 Rotterdam consensus definition of PCOS 20 (though as a group they have an increased prevalence of ultrasound-confirmed PCO morphology compared with controls), 26 we label these as 'symptomatic cases'. Available phenotypic data include BMI, serum testosterone and SHBG. Clinical features are provided in Table 1 . Serum testosterone and SHBG concentrations in the UK and Finnish groups were measured as described previously. 21 Free androgen index (FAI) was calculated as total testosterone Â 100/SHBG. All clinical investigations were conducted in accordance with the guidelines in the Declaration of Helsinki, and the study was approved by the relevant ethics committees in the United Kingdom and Finland. All subjects provided fully informed consent.
Genotyping
In UK cases and HRC þ controls, the E23K variant (rs5219:C4T) was typed using a PCR-restriction fragment 
Results

UK case -control sample
In the absence of significant genotype frequency differences at E23K between the two UK control subgroups, or between genders, the principal case -control analysis compared UK cases against the entire control group ( oral hypoglycaemic agents (and after exclusion of those women pregnant at the time of examination in the Finnish groups). There were no significant differences in testosterone concentrations or FAI with respect to E23K genotype in any of the groups (Table 3) , nor was there any consistent pattern or trend across the three groups.
Discussion
This is the first study to analyse the relationship between variation at the KCNJ11 E23K polymorphism and PCOS. In case -control and quantitative trait analyses, we found no evidence that this variant was associated with the development of PCOS, or related to relevant quantitative traits (principally, androgen measures).
Because there are over 20 000 genes in the human genome, the biological significance of this finding depends in large part on the credibility of the E23K variant within KCNJ11 as a candidate for PCOS. The E23K variant is established as one of the few polymorphisms with a convincingly replicated impact on T2D susceptibility. In vitro 19 and in vivo 30 functional studies indicate that the K allele at E23K is associated with an increased open probability of the beta-cell K ATP channel and reduced insulin secretion. 19 In this respect, the strong clinical, phenotypic and epidemiological overlap between T2D and PCOS promotes a powerful argument for overlapping genetic influences. However, the relationships between PCOS, T2D and insulin levels are complex. Although, as with T2D, PCOS is characterised by peripheral insulin resistance, a wide range of abnormalities of beta-cell function have also been reported. These include both reduced beta-cell function, 31 -34 and increased acute insulin secretion from the beta cell during an oral glucose tolerance test. 35, 4, 36 These This provides a mechanism whereby the ovary is subjected to excessive insulin action despite peripheral insulin resistance and appropriate, but inadequate, compensatory hyperinsulinaemia. Under such a model, a variant such as E23K that influences beta-cell function might, in principle, be capable both of increasing the risk of T2D and reducing that of PCOS. The present study would, of course, have been able to detect powerful associations in either direction. In the absence of a significant association with PCOS, these genetic data do not allow us to distinguish between these alternative mechanisms.
It is important to realise, however, that while the present study involves data on over 4600 individuals, the available sample sizes place inevitable limitations on interpretation of these findings. The numbers in either the UK or Finnish case -control subsets were sufficient to detect an OR 41.25 (with a ¼ 0.05 and 80% power). Although this OR threshold roughly equates to the effect size of E23K on susceptibility to T2D seen in early meta-analyses, 17 more recent meta-analyses have suggested that the effect of E23K on T2D susceptibility is lower (ORB1.15). 16, 37 The power of the present study to detect effect sizes with ORo1.25 is limited. Furthermore, ovarian ultrasound data were not available for most of the Finnish symptomatic cases. Therefore, the possibility of false negative results in the Finnish analyses cannot be excluded. In summary, our study provides no evidence that variation at the KCNJ11 E23K polymorphism, known to be associated with diabetes risk, influences PCOS susceptibility or levels of androgens. These data argue against a direct overlap in genetic susceptibility between T2D and PCOS. However, analysis of samples several times larger than those available in this study (or most other current studies of PCOS genetics for that matter) would be required to exclude variation at the KCNJ11 E23K polymorphism from a more modest role in disease susceptibility.
